… , nirmatrelvir plus ritonavir received authorization in the EU for use in the same indication.
Nirmatrelvir plus ritonavir is … in the development of nirmatrelvir plus ritonavir leading to its first …

… -19 at high risk for progression to severe disease. The incidence of … nirmatrelvir plus ritonavir
than with placebo. The efficacy of … nirmatrelvir exposure; therefore, nirmatrelvir plus ritonavir …

… plus 100 mg of ritonavir every 12 hours for 5 days… nirmatrelvir–ritonavir as the active
control for comparison with VV116 was based on the established superiority of nirmatrelvir–ritonavir …

… molnupiravir, while 43.2% received nirmatrelvir/ritonavir. Patients in the molnupiravir group
… had a higher rate of chronic heart disease than those treated with nirmatrelvir/ritonavir. Three …

… severe COVID-19. Our objective was to evaluate the effectiveness of nirmatrelvir–ritonavir
in preventing severe … We compared patients treated with nirmatrelvir–ritonavir with patients …

… COVID-19 and eligible for nirmatrelvir-ritonavir treatment, a systematic review …
nirmatrelvir-ritonavir. The objective of this study was to evaluate the performance of …

… In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12 years …
severe disease and hospitalisation. We aimed to establish the effectiveness of nirmatrelvir–ritonavir …

… Adverse events occurred more frequently in the nirmatrelvir/ritonavir group (49.2%).
Nirmatrelvir/ritonavir compared with remdesivir was associated with a higher probability of having a …

… The nirmatrelvir/ritonavir group included all patients meeting inclusion … nirmatrelvir/ritonavir;
the non-nirmatrelvir/ritonavir group included those not prescribed nirmatrelvir/ritonavir or …

… to nirmatrelvir–ritonavir use, or had severe renal or severe liver impairment were excluded.
Patients who received the oral antivirals molnupiravir or nirmatrelvir–ritonavir were matched …